JAMP-CANDESARTAN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CANDESARTAN CILEXETIL

Prieinama:

JAMP PHARMA CORPORATION

ATC kodas:

C09CA06

INN (Tarptautinis Pavadinimas):

CANDESARTAN

Dozė:

16MG

Vaisto forma:

TABLET

Sudėtis:

CANDESARTAN CILEXETIL 16MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0135220003; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2012-06-06

Prekės savybės

1
PRODUCT MONOGRAPH
PR
JAMP-CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Angiotensin II
AT
1
Receptor Blocker
JAMP PHARMA CORPORATION
1310
rue
Nobel
Boucherville,
Québec J4B 5H3
Control No. : 229652
Date of Approval:
April 17, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE REACTIONS
..................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND
ADMINISTRATION.........................................................................
18
O V E R D O S A GE
..........................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................... 21
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
.................................................................................25
PHARMACEUTICAL INFORMATION
25
CLINICAL TRIALS
..........................................................................................................
26
DETAILED PHARMACOLOGY
.................................................................................
30
TO X IC OLO G Y
....................................................